公开(公告)号：EP4321535A1

公开(公告)日：2024-02-14

申请号：EP22784923.9

申请日：2022-04-05

申请人： Genome and Company

发明人： JEON, Bu Nam ,  CHUNG, Joo Yeon ,  MOON, Soo Jung ,  KIM, Hyunuk ,  CHA, Mi Young ,  CHUNG, Junho ,  JIN, Junyeong ,  KIM, Soohyun ,  CHAE, Jisu

IPC分类号： C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  A61K39/00

摘要： The present invention relates to an anti-CNTN4 antibody or an antigen-binding fragment thereof, a pharmaceutical composition containing the same, and a use thereof for activating T cells upregulating cell-mediated immune responses, for example, for treating cancer.

公开(公告)号：EP4435090A1

公开(公告)日：2024-09-25

申请号：EP22895764.3

申请日：2022-05-20

申请人： Genome and Company

发明人： KIM, Hyerim ,  LEE, Suro ,  YEON, Jaesung ,  KIM, Hyeyoung ,  LEE, Donghun

IPC分类号： C12N1/20 ,  A61K35/742 ,  A61P15/08 ,  A23L33/135 ,  C12R1/25

CPC分类号： A61P15/08 ,  C12N1/20 ,  C12R2001/02520210501 ,  A61K35/742 ,  A23L33/135

摘要： The present invention relates to a novel Lactobacillus plantarum strain. In addition, the present invention relates to a composition for preventing, improving, or treating infertility or subfertility comprising the Lactobacillus plantarum strain.
The Lactobacillus plantarum strain of the present invention reduces the expression of specific genes in cells constituting the placenta to help implantation of the embryo, increases the number of immune cells in the uterus, and enhances the implantation rate of embryos reduced by immune imbalance. Accordingly, it can be effectively utilized as a composition for the prevention, improvement, or treatment of infertility or subfertility.

公开(公告)号：EP4321174A1

公开(公告)日：2024-02-14

申请号：EP22785005.4

申请日：2022-04-07

申请人： Genome and Company

发明人： JEON, Bu-Nam ,  CHA, Mi Young

IPC分类号： A61K39/395 ,  A61K48/00 ,  A61K31/713 ,  A61P35/00 ,  A61P37/02 ,  G01N33/50 ,  C07K16/28 ,  C07K14/78 ,  A61K39/00

摘要： The present disclosure relates to a pharmaceutical composition for treating or preventing cancer, a pharmaceutical composition for immune-enhancing, a method of screening of anti-cancer agent, and a method of providing information necessary for analysis of cancer prognosis. According to the present disclosure, cancer can be effectively prevented or treated using a CNTN4 inhibitor, and the immunity of subject can be enhanced. In addition, the present disclosure is very useful because it can effectively select new anticancer drug candidates by determining the activity or expression of CNTN4 and can provide information necessary for diagnosing and predicting cancer prognosis.

公开(公告)号：EP3775889A1

公开(公告)日：2021-02-17

申请号：EP19781413.0

申请日：2019-04-03

申请人： Genome and Company

发明人： YOON, Kyoung-Wan ,  JEON, Bu-Nam ,  SOHN, Jinyoung ,  KIM, Yun Yeon ,  LEE, Suro ,  HOUH, Youn Kyung ,  CHUNG, Joo-Yeon ,  JEONG, Areum

IPC分类号： G01N33/50 ,  G01N33/68 ,  C12Q1/6886

公开(公告)号：EP3795585A1

公开(公告)日：2021-03-24

申请号：EP19804458.8

申请日：2019-05-15

申请人： Genome and Company

发明人： YOON, Kyoung Wan ,  HOUH, Youn Kyung ,  JEON, Bu-Nam ,  SOHN, Jinyoung ,  KIM, Yun Yeon ,  LEE, Suro ,  CHUNG, Joo-Yeon ,  JEONG, Areum

IPC分类号： C07K14/705 ,  C07K16/28 ,  A61P31/00 ,  A61P35/00 ,  A61K38/00

摘要： The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising an LRIT2 inhibitor as an active ingredient. The LRIT2 inhibitor according to the present invention can increase the activity of immune cells, and thus can be used as an immune enhancer. Also, the LRIT2 inhibitor according to the present invention can effectively prevent or treat cancer by enhancing the immunity of an individual.

公开(公告)号：EP3737945A1

公开(公告)日：2020-11-18

申请号：EP19738069.4

申请日：2019-01-11

申请人： Genome and Company

发明人： YOON, Kyoung-Wan ,  SOHN, Jinyoung ,  KIM, Yun Yeon ,  LEE, Suro ,  HOUH, Youn Kyung ,  CHUNG, Joo-Yeon ,  JEONG, Areum

IPC分类号： G01N33/50 ,  C12Q1/6886

公开(公告)号：EP4046645A1

公开(公告)日：2022-08-24

申请号：EP20876177.5

申请日：2020-10-16

申请人： Genome and Company ,  Gwangju Institute of Science and Technology

发明人： PARK, Hansoo ,  SOHN, Jinyoung ,  KIM, Yul Ha

IPC分类号： A61K35/745 ,  A61P37/00

摘要： The present invention relates to a composition for enhancing or improving immunity comprising a Bifidobacterium bifidum. In addition, it can be used to prevent, treat, or improve immune diseases caused by immunodeficiency, immunosuppression, or immune system damage. It can be provided as a food composition or a pharmaceutical composition, and the food composition can be provided in various forms such as probiotic products, health functional supplements, animal feed, and the like.

公开(公告)号：EP4342914A1

公开(公告)日：2024-03-27

申请号：EP21940919.0

申请日：2021-06-01

申请人： Genome and Company

发明人： CHA, Mi Young ,  YU, Hyunkyung ,  JEON, Bu Nam ,  KIM, Hyunuk

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K39/00

摘要： The present invention relates to an anti-BCAM antibody or an antigen-binding fragment thereof, and uses thereof. In addition, the anti-BCAM antibody or antigen-binding fragment thereof according to the present invention can be used for preventing or treating a state associated with cells expressing BCAM, for example, cancer..

公开(公告)号：EP4332116A1

公开(公告)日：2024-03-06

申请号：EP21939415.2

申请日：2021-04-29

申请人： Genome and Company

发明人： JEON, Bu Nam ,  HOUH, Youn Kyung ,  KIM, Yun Yeon ,  CHA, Mi Young

IPC分类号： C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  G01N33/577 ,  A61K39/00

摘要： The present invention relates to anti-CNTN4 antibodies or antigen-binding fragments thereof, and use thereof for activating T cells that upregulate a cell-mediated immune response, for example, use thereof for the treatment of cancer.

公开(公告)号：EP3805258A1

公开(公告)日：2021-04-14

申请号：EP19812551.0

申请日：2019-05-30

申请人： Genome and Company

发明人： YOON, Kyoung Wan ,  HOUH, Youn Kyung ,  JEON, Bu-Nam ,  SOHN, Jinyoung ,  KIM, Yun Yeon ,  LEE, Suro ,  CHUNG, Joo-Yeon ,  JEONG, Areum

IPC分类号： C07K14/705 ,  A61K47/68 ,  A61P27/14 ,  A61P31/00 ,  A61P35/00 ,  A61P37/04 ,  A61P37/06 ,  A61K38/00

摘要： The present invention relates to a pharmaceutical composition for preventing or treating cancer, containing a CD300E inhibitor as an active ingredient. The CD300E inhibitor according to the present invention can increase the activity of immunocytes so as to be usable as an adjuvant. In addition, the CD300E inhibitor according to the present invention enhances the immunity of an individual, thereby enabling cancer to be effectively prevented or treated.